13 completed, 6 terminated, 3 active not recruiting, 2 unknown. 27 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 13, Terminated 6, Active not recruiting 3, Unknown 2, Withdrawn 2, Recruiting 1 |
| Phase 2 | 12 | Terminated 6, Completed 3, Unknown 2, Withdrawn 1 |
Follow merphos: new trials by email Literature Review of merphos trials Research Report on merphos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome | Phase 1 | Recruiting | Children's Oncology Group | 36 | 2025-02-04 | 2026-08-25 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2022-03-17 | 2026-05-28 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test - Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 47 | 2021-05-24 | 2026-10-19 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Fludarabine Phosphate - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2019-05-17 | 2025-04-13 |
| Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 53 | 2019-04-03 | 2026-05-13 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | OHSU Knight Cancer Institute | 7 | 2016-01-13 | 2020-05-26 |
| Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma carfilzomib, cyclophosphamide, vincristine sulfate - Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Phase 1 | Completed | Mehrdad Abedi, MD | 10 | 2015-12-17 | 2022-03-10 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1 / Phase 2 | Unknown | Northwestern University | 38 | 2015-10-28 | 2022-02-21 |
| Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies radiation therapy, cyclophosphamide, anti-thymocyte globulin - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 1 | Completed | Sumithira Vasu | 33 | 2015-07-27 | 2023-09-21 |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma | Phase 1 | Completed | OHSU Knight Cancer Institute | 11 | 2015-07-20 | 2020-11-23 |
| Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults MLN 9708, Vincristine, Cytarabine - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | Completed | Massachusetts General Hospital | 19 | 2014-12-01 | 2019-11-26 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies total marrow irradiation, fludarabine phosphate, busulfan - Acute Myeloid Leukemia, Hematologic Malignancies | Phase 1 | Completed | Case Comprehensive Cancer Center | 14 | 2014-11-05 | 2021-05-07 |
| Allogeneic Stem Cell Transplant for CLL Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2012-11-21 | 2020-02-24 |
| CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin - Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 27 | 2012-10-29 | 2024-07-23 |
| A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Decitabine, Vorinostat, Vincristine - Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | Therapeutic Advances in Childhood Leukemia Consortium | 23 | 2011-12-01 | 2020-10-27 |
Showing 20 of 27. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Burkitt Lymphoma (7) · Leukemia, Myeloid, Acute (7) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (4) · Hematologic Neoplasms (3) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Myelodysplastic Syndromes (3) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, T-Cell (2) · Multiple Myeloma (2) · Congenital Abnormalities (1) · Hodgkin Disease (1) · Leukemia (1)
M.D. Anderson Cancer Center (7) · Children's Oncology Group (5) · National Cancer Institute (NCI) (4) · OHSU Knight Cancer Institute (4) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Massachusetts General Hospital (1) · Mehrdad Abedi, MD (1) · Northwestern University (1) · Sumithira Vasu (1) · Therapeutic Advances in Childhood Leukemia Consortium (1)
United States (25) · Australia (3) · Canada (3) · Puerto Rico (1)
Alexandra M Stevens (1) · Alvaro J Alencar (1) · Barbara Pro, MD (1) · Ben K Watkins (1) · Chitra Hosing (1) · Edward A Neuwelt (1) · Elias Jabbour (1) · Elizabeth Raetz, MD (1) · Ibrahim T Aldoss (1) · Issa Khouri (1) · Issa Khouri, MD (1) · Jessica T Leonard (1) · John Sandlund (1) · Katherine G Tarlock (1)
PMID 23233571, PMID 25145344, PMID 31969338, PMID 36841758, PMID 38207208, PMID 38237077
U10CA098543 (3), P30CA016672 (2), U10CA180886 (2), UM1CA228823 (2), P30CA033572 (1), P30CA060553 (1), P30CA069533 (1), R01CA137488 (1), U01CA097452 (1), U10CA098413 (1), U10CA180821 (1), U10CA180899 (1)